K Pharma,Inc. Logo

K Pharma,Inc.

Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.

4896 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区六本木七丁目7番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

K Pharma, Inc. is a biotechnology company established as a spin-off from the Keio University School of Medicine to commercialize research in induced pluripotent stem (iPS) cell technology. The company engages in the research, development, manufacturing, and sale of pharmaceuticals and regenerative medicine products. Its business is centered on two key areas: iPS drug discovery, which utilizes disease-specific iPS cells to develop new therapies, and regenerative medicine. The company's primary therapeutic focus is on the central nervous system (CNS), developing applications for nerve regeneration to treat conditions such as spinal cord injuries and cerebral infarctions.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for K Pharma,Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 02:30
Interim Report
半期報告書-第9期(2025/01/01-2025/12/31)
Japanese 179.3 KB
2025-08-14 02:30
Regulatory News Service
確認書
Japanese 8.8 KB
2025-03-28 02:01
Regulatory News Service
臨時報告書
Japanese 24.2 KB
2025-03-28 02:00
Regulatory News Service
内部統制報告書-第8期(2024/01/01-2024/12/31)
Japanese 22.4 KB
2025-03-28 02:00
Annual Report
有価証券報告書-第8期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2025-03-28 02:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-08-14 08:00
Regulatory News Service
確認書
Japanese 8.9 KB
2024-08-14 08:00
Interim Report
半期報告書-第8期(2024/01/01-2024/12/31)
Japanese 182.0 KB
2024-05-14 02:00
Quarterly Report
四半期報告書-第8期第1四半期(2024/01/01-2024/03/31)
Japanese 136.5 KB
2024-05-14 02:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-03-29 02:30
Regulatory News Service
臨時報告書
Japanese 22.6 KB
2024-03-28 07:01
Regulatory News Service
確認書
Japanese 8.8 KB
2024-03-28 07:00
Regulatory News Service
内部統制報告書-第7期(2023/01/01-2023/12/31)
Japanese 22.4 KB
2024-03-28 07:00
Annual Report
有価証券報告書-第7期(2023/01/01-2023/12/31)
Japanese 1.5 MB
2023-11-13 07:01
Regulatory News Service
確認書
Japanese 8.8 KB

Automate Your Workflow. Get a real-time feed of all K Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for K Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875

Talk to a Data Expert

Have a question? We'll get back to you promptly.